HER2-positive breast cancer: Biomarker analysis identified women most likely to benefit from T-DM1 | Cáncer de mama | Scoop.it
For women with metastatic, HER2-positive breast cancer, the amount of HER2 on their tumor might determine how much they benefit from a drug called trastuzumab emtansine (T-DM1), according to data from a subanalysis of the phase III clinical trial...

Via Curated by A4BC.ORG